Adhera Therapeutics, Inc. (ATRX)

OTCMKTS: ATRX · Delayed Price · USD
0.0130
0.00 (0.00%)
Feb 27, 2024, 2:28 PM EST - Market closed
Market Cap 93.87K
Revenue (ttm) n/a
Net Income (ttm) -2.53M
Shares Out 7.22M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 20,101
Open 0.0135
Previous Close 0.0130
Day's Range 0.0130 - 0.0135
52-Week Range 0.0100 - 0.9200
Beta -0.11
Analysts n/a
Price Target n/a
Earnings Date n/a

About ATRX

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Andrew Albert Kucharchuk M.B.A.
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol ATRX
Full Company Profile

Financial Performance

Financial Statements

News

Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes

Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Comp...

1 year ago - GlobeNewsWire

Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist

Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8...

1 year ago - GlobeNewsWire

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has...

1 year ago - GlobeNewsWire

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointmen...

1 year ago - GlobeNewsWire

Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board

Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointm...

2 years ago - GlobeNewsWire

Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace

Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successfu...

2 years ago - GlobeNewsWire

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Ca...

2 years ago - GlobeNewsWire

Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors

Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointme...

2 years ago - GlobeNewsWire

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Baton Rouge, LA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has...

2 years ago - GlobeNewsWire

Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease

IP Estate Grows with New Korean Patent Issued

2 years ago - GlobeNewsWire

Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias

Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Eu...

2 years ago - GlobeNewsWire

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson's Disease and Type 1 Diabetes Drugs

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an upda...

2 years ago - GlobeNewsWire